MEDP — Medpace Holdings, Inc.

Medpace Holdings, Inc. (MEDP) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $708.5 million, up 32% year-over-year.
• Full Year 2025 Revenue: $2.53 billion, a 20% increase from 2024.
• Net New Business Awards (Q4): $736.6 million, 39.1% increase year-over-year, resulting in a net book-to-bill ratio of 1.04.
• Full Year Net New Business Awards: $2.65 billion, up 18.7%.
• Ending Backlog: Approximately $3 billion, a 4.3% increase from the prior year.
• EBITDA (Q4): $160.2 million, a 20% increase; full year EBITDA was $557.7 million, up 16.1%.
• Net Income (Q4): $135.1 million, a 15.5% increase; full year net income was $451.1 million, up 11.6%.
• Net Income per Diluted Share (Q4): $4.67; full year was $15.28.
• Cash from Operating Activities (Q4): $192.7 million; cash balance at year-end was $497 million.
• Share Repurchases: 2.96 million shares for $912.9 million in 2025.

2. Strategic Updates and Business Highlights

• Cancellations: Elevated backlog cancellations were noted, the highest in over a year, impacting the net book-to-bill ratio.
• Backlog Conversion Rate: 23.6% for Q4, indicating a healthy conversion potential despite cancellations.
• Hiring Plans: Anticipated accelerated hiring in 2026, with mid to high single-digit growth expected.
• AI Initiatives: Ongoing investments in AI to improve efficiency and data analytics, though no immediate productivity advantages expected in 2026.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $2.755 billion and $2.855 billion, representing growth of 8.9% to 12.8% over 2025.
• 2026 EBITDA Guidance: Projected between $605 million and $635 million, indicating growth of 8.5% to 13.9%.
• Net Income Guidance for 2026: Expected between $487 million and $511 million, with earnings per diluted share projected to be between $16.68 and $17.50.

4. Bad News, Challenges, or Points of Concern

• Cancellation Rates: Elevated cancellations in Q4, particularly in the metabolic therapeutic area, which could signal potential volatility in future bookings.
• Margin Pressure: EBITDA margins decreased slightly, impacted by higher reimbursable costs and a shift in therapeutic mix.
• Competitive Landscape: Increased aggressiveness from top CROs in the market, although management did not perceive significant changes in competitive dynamics.
• Economic Environment: Concerns about the broader economic environment affecting client funding and project decisions.

5. Notable Q&A Insights

• Cancellations: Management indicated that cancellations were widespread and not concentrated among a few clients, with no clear pattern observed.
• Revenue Growth Expectations: While direct service revenue guidance was not provided, management expects a flatter top-line growth cadence throughout 2026.
• AI Impact: Management expressed caution regarding the immediate benefits of AI, suggesting that while investments are being made, significant productivity gains may not materialize in the near term.
• Therapeutic Area Concentration: The company acknowledged risks associated with concentration in the metabolic area but did not see it as a major concern at this time.

Overall, while Medpace reported strong financial growth and positive forward guidance, challenges related to elevated cancellations and competitive pressures were highlighted as areas to monitor closely.